The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 8, 2014, Pages 655-666

  Hegele, Robert A ^a   Ginsberg, Henry N ^b   Chapman, M John ^c   Nordestgaard, Børge G ^d   Kuivenhoven, Jan Albert ^e   Averna, Maurizio ^f   Borén, Jan ^g   Bruckert, Eric ^c   Catapano, Alberico L ^h   Descamps, Olivier S ⁱ   Hovingh, G Kees ^j   Humphries, Steve E ^k   Kovanen, Petri T ^l   Masana, Luis ^m   Pajukanta, Päivi ⁿ   Parhofer, Klaus G ^o   Raal, Frederick J ^p   Ray, Kausik K ^q   Santos, Raul D ^r   Stalenhoef, Anton F H ^s   Stroes, Erik ^j   Taskinen, Marja Riitta ^t   Tybjærg Hansen, Anne ^d   Watts, Gerald F ^u   Wiklund, Olov ^v   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Howard Hughes Medical Institute   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Hospital de Jolimont   (Belgium)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l WIHURI RESEARCH INSTITUTE   (Finland)

^m UNIVERSITAT ROVIRA I VIRGILI   (Spain)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF MUNICH   (Germany)

^p UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^q ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^r UNIVERSITY OF SÃO PAULO   (Brazil)

^s RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^t HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^u UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^v UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; FATTY ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ALLELE; AUTOSOMAL RECESSIVE DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; EXERCISE; FAMILIAL DISEASE; FAMILY COUNSELING; FAMILY STUDY; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; LIFESTYLE; LIPID ANALYSIS; MOLECULAR PATHOLOGY; MONOGENIC DISORDER; NONHUMAN; PANCREATITIS; PHARMACEUTICAL CARE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; RARE DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; GENETIC PREDISPOSITION; GENETICS; HEALTH PROMOTION; MULTIFACTORIAL INHERITANCE; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE;

ANIMALS; BIOMARKERS; COMBINED MODALITY THERAPY; GENETIC PREDISPOSITION TO DISEASE; HEALTH PROMOTION; HUMANS; HYPERTRIGLYCERIDEMIA; LIFE STYLE; MULTIFACTORIAL INHERITANCE; PRACTICE GUIDELINES AS TOPIC; TRIGLYCERIDES;

EID: 84906937463     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70191-8     Document Type: Review

References (68)

1. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012, 97:2969-2989. the Endocrine Society.
2. Boullart AC, de Graaf J, Stalenhoef AF Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 2012, 1821:867-875.
3. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361. the European Atherosclerosis Society Consensus Panel.
4. Yuan G, Al-Shali KZ, Hegele RA Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007, 176:1113-1120.
5. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in AdultsTreatment of High Blood Cholesterol in Adults.
6. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(suppl 1):S1-44. the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS)the European Atherosclerosis Society (EAS), the ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committeesthe ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees.
7. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818. the European Association for Cardiovascular Prevention & Rehabilitation, the ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committeesthe ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.
8. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
9. Sarwar N, Sattar N Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?. Curr Opin Lipidol 2009, 20:275-281.
10. Goussault Y, Turpin E, Neel D, et al. 'Pseudohypertriglyceridemia' caused by hyperglycerolemia due to congenital enzyme deficiency. Clin Chim Acta 1982, 123:269-274.
11. Langsted A, Nordestgaard BG Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 2011, 57:482-489.
12. Guerin M, Egger P, Soudant C, et al. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res 2002, 43:1652-1660.
13. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
14. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152.
15. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436.
16. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013, 34:1826-1833.
17. Nordestgaard BG, Benn M Fasting and nonfasting LDL cholesterol: to measure or calculate?. Clin Chem 2009, 55:845-847.
18. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
19. Zilversmit DB Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
20. Nordestgaard BG, Wootton R, Lewis B Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995, 15:534-542.
21. Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321-327.
22. Malloy MJ, Kane JP A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 2001, 47:111-136.
23. Mamo JC, Proctor SD, Smith D Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998, 141(suppl 1):S63-S69.
24. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. the Emerging Risk Factors Collaboration.
25. Ng DS, Wong NC, Hegele RA HDL-is it too big to fail?. Nat Rev Endocrinol 2013, 9:308-312.
26. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. The Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
27. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013, 45:1345-1352.
28. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
29. Sacks FM, Carey VJ, Fruchart JC Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-694.
30. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267. the AIM-HIGH Investigators.
31. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033.
32. Fredrickson DS, Lees RS A system for phenotyping hyperlipoproteinemia. Circulation 1965, 31:321-327.
33. Hegele RA Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009, 10:109-121.
34. Soutar AK, Naoumova RP Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007, 4:214-225.
35. Hegele RA, Ban MR, Hsueh N, et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009, 18:4189-4194.
36. Johansen CT, Wang J, Lanktree MB, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2011, 31:1916-1926.
37. Johansen CT, Kathiresan S, Hegele RA Genetic determinants of plasma triglycerides. J Lipid Res 2011, 52:189-206.
38. Johansen CT, Hegele RA Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011, 22:247-253.
39. Johansen CT, Hegele RA Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta 2012, 1821:833-842.
40. Nordestgaard BG, Freiberg JJ Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol 2011, 9:281-286.
41. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013, 381:1293-1301.
42. Beil U, Grundy SM, Crouse JR, Zech L Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis 1982, 2:44-57.
43. Rahalkar AR, Giffen F, Har B, et al. Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can J Physiol Pharmacol 2009, 87:151-160.
44. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 1989, 9:326-334.
45. Hegele RA, Breckenridge WC, Cox DW, Maguire GF, Little JA, Connelly PW Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations. Arterioscler Thromb 1991, 11:1303-1309.
46. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997, 96:1737-1744.
47. Priore Oliva C, Pisciotta L, Li Volti G, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005, 25:411-417.
48. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010, 42:684-687.
49. Johansen CT, Wang J, McIntyre AD, et al. Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet 2012, 5:66-72.
50. Lee JH, Giannikopoulos P, Duncan SA, et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med 2011, 17:812-815.
51. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
52. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
53. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
54. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. the Cholesterol Treatment Trialists' (CTT) Collaborators.
55. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012, 223:251-261.
56. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307:1302-1309.
57. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
58. HPS2-THRIVE University of Oxford Clinical Trial Service Unit, Epidemiological Studies UnitEpidemiological Studies Unit, (accessed Nov 28, 2013). http://www.ctsu.ox.ac.uk/research/mega-trials/hps2-thrive.
59. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010, 32:615-625. the Triple Study Group.
60. Asselbergs FW, Guo Y, van Iperen EP, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012, 91:823-838. the LifeLines Cohort Study.
61. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307.
62. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012, 489:391-399.
63. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010, 11:55-60.
64. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008, 28:2303-2304.
65. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46. the Phase 3 HoFH Lomitapide Study investigators.
66. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
67. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.
68. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010, 363:2220-2227.